Zhitong Finance App News, Cansino Biotech (06185) issued an announcement. The company is concerned about the recent development of mRNA technology in the market. The mRNA platform is one of the company's key technology platforms. The company is developing mRNA preventive vaccines and therapeutic biological products, as well as related delivery systems. In the field of treatment, the company is promoting research and development of mRNA vaccines for the treatment of indications such as glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of in vivo CAR-related therapies, which are currently in the early stages.

Recently, the company's subsidiary Cansino (Shanghai) Biological Research & Development Co., Ltd. (Cansino Shanghai) and Deputh (Hangzhou) Biotechnology Co., Ltd. (Deputh Biotech) signed a strategic cooperation framework agreement for the joint development of personalized mRNA oncology vaccines. According to the strategic cooperation framework agreement, the two sides will use their respective advantages in mRNA vaccine technology and the discovery and design of novel tumor antigens to jointly explore cooperation.

The board of directors believes that the development of the company's mRNA technology platform and the establishment of a strategic cooperation framework agreement are in line with the company's long-term strategy and in line with the overall interests of the company and its shareholders.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.